{
    "clinical_study": {
        "@rank": "125964", 
        "acronym": "START", 
        "arm_group": {
            "arm_group_label": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells", 
            "arm_group_type": "Experimental", 
            "description": "This is a dose-escalation Phase 1 clinical trial with 3 cohorts with 3 subjects/cohort who will receive doses of 1 million cells/kg, 5 million cells/kg, and 10 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort of 3 patients."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic\n      Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute\n      Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of\n      hMSCs in patients with ARDS."
        }, 
        "brief_title": "Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Respiratory Distress Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to assess the safety of intravenous infusion of\n      Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients will be eligible for inclusion if they meet all of the below criteria. Criteria\n        1-3 must all be present within a 24-hour time period and at the time of enrollment:\n\n        Acute onset (defined below) of:\n\n          1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a\n             PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure\n             (PEEP)\n\n          2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph\n\n          3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.\n\n        In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first\n        meeting ARDS criteria per the Berlin definition of ARDS.\n\n        Exclusion Criteria:\n\n          1. Age less than 18 years\n\n          2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of\n             ARDS\n\n          3. Pregnant or breast-feeding\n\n          4. Prisoner\n\n          5. Presence of any active malignancy (other than non-melanoma skin cancer) that required\n             treatment within the last 2 years\n\n          6. Any other irreversible disease or condition for which 6-month mortality is estimated\n             to be greater than 50%\n\n          7. Moderate to severe liver failure (Childs-Pugh Score > 12)\n\n          8. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen\n\n          9. Patient, surrogate, or physician not committed to full support (exception: a patient\n             will not be excluded if he/she would receive all supportive care except for attempts\n             at resuscitation from cardiac arrest).\n\n         10. Major trauma in the prior 5 days\n\n         11. Lung transplant patient\n\n         12. No consent/inability to obtain consent\n\n         13. Moribund patient not expected to survive 24 hours\n\n         14. WHO Class III or IV pulmonary hypertension\n\n         15. Documented deep venous thrombosis or pulmonary embolism within past 3 months\n\n         16. No arterial line/no intent to place an arterial line\n\n         17. No intent/unwillingness to follow lung protective ventilation strategy or fluid\n             management protocol\n\n         18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory\n             ventilation (HFOV)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775774", 
            "org_study_id": "ARDS MSC 001", 
            "secondary_id": "1U01HL108713-01"
        }, 
        "intervention": {
            "arm_group_label": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells", 
            "description": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.", 
            "intervention_name": "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute Respiratory Distress Syndrome", 
            "Acute Lung Injury", 
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
        ], 
        "lastchanged_date": "January 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California San Francisco Medical Center"
                }, 
                "investigator": {
                    "last_name": "Michael A Matthay, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rvojnik@stanford.edu", 
                    "last_name": "Rosemary Vojnik, BS", 
                    "phone": "(650) 723-7409"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Joseph Eric Levitt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kcosgrove@partners.org", 
                    "last_name": "Katherine Cosgrove, RN", 
                    "phone": "617-726-3498"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Taylor B Thompson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh Medical Center"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome", 
        "overall_contact": {
            "email": "michael.matthay@ucsf.edu", 
            "last_name": "Michael A Matthay, MD", 
            "phone": "415-353-1206"
        }, 
        "overall_contact_backup": {
            "email": "hanjing.zhuo@ucsf.edu", 
            "last_name": "Hanjing Zhuo, MPH", 
            "phone": "415-502-7434"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Comparison of treatment adverse event rates between the 1, 5 and 10 million cells per kilogram dose cohorts", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775774"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Michael A. Matthay", 
            "investigator_title": "Prinicpal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Massachusetts General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Stanford University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Pittsburgh", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Michael A. Matthay", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}